Respiratory Research, Journal Year: 2025, Volume and Issue: 26(1)

Published: March 28, 2025

Human rhinovirus (HRV), a non-enveloped RNA virus, was first identified more than 70 years ago. It is highly infectious and easily transmitted through aerosols direct contact. The advent of multiplex PCR has enhanced the detection diverse range respiratory viruses, HRV consistently ranks among most prevalent pathogens globally. Circulation occurs throughout year, with peak incidence in autumn spring temperate climates. Remarkably, during SARS-CoV-2 pandemic, transmission persisted, demonstrating its resistance to stringent public health measures aimed at curbing viral transmission. characterised by extensive genetic diversity, comprising three species 170 genotypes. This diversity substantial number concurrently circulating strains allows HRVs frequently escape adaptive immune system poses formidable challenges for development effective vaccines antiviral therapies. There currently lack specific treatments. Historically, been associated self-limiting upper infection. However, there now evidence highlighting significant role severe lower disease adults, including exacerbations chronic airway diseases, such as asthma obstructive pulmonary (COPD), well pneumonia. These manifestations can occur even immunocompetent individuals, broadening clinical impact this ubiquitous virus. Consequently, burden infections extends across various healthcare settings, from primary care general hospital wards intensive units. terms morbidity utilisation, rivals that other major influenza syncytial Recognition underscores critical need novel treatment strategies management protocols mitigate on health. review examines epidemiology, manifestations, risk factors infection adults. By drawing contemporary literature, we aim provide comprehensive overview virus's implications. Understanding scope essential developing new, targeted interventions improving patient outcomes face persistent adaptable pathogen.

Language: Английский